Isroen

Clopidogrel, the active ingredient in Isroen, is an antiplatelet agent presented as an oral tablet for oral use. It helps reduce the risk of blood clots in patients with cardiovascular disease, including those who have experienced heart attacks, strokes, or have undergone coronary procedures. It is commonly prescribed to lower the incidence of myocardial infarction, ischemic stroke, and peripheral arterial disease in at‑risk populations.

GNH USA supplies Isroen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Clopidogrel is used to inhibit platelet aggregation in various cardiovascular and cerebrovascular conditions. - Prevention of thrombotic events: Reduces the risk of clot formation in patients with established atherosclerotic disease. - Acute coronary syndrome: Decreases incidence of recurrent myocardial infarction and cardiovascular death in ACS patients. - Post‑percutaneous coronary intervention: Prevents stent thrombosis and related complications after PCI. - Stroke prevention: Lowers the chance of ischemic stroke in patients with prior stroke or transient ischemic attack.

Clopidogrel may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Diarrhea: loose stools, often transient. - Nausea: feeling of sickness or urge to vomit. - Bruising: easy bruising or minor bleeding from skin.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Thrombotic thrombocytopenic purpura: rare blood disorder with low platelets. - Neutropenia: significant reduction in white blood cells. - Hypersensitivity reactions: rash, fever, or anaphylaxis.

When prescribing clopidogrel, clinicians should consider several precautionary measures to ensure patient safety. - Assess bleeding risk: evaluate history of hemorrhage or anticoagulant use. - Monitor liver function: check hepatic enzymes in patients with liver disease. - Use caution in renal impairment: adjust therapy in severe kidney dysfunction. - Avoid in active pathological bleeding: discontinue if uncontrolled bleeding occurs. - Review concomitant medications: consider potential drug interactions that may increase bleeding. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Clopidogrel can interact with other medicines, affecting its antiplatelet efficacy or bleeding risk.

Major Interactions (Avoid): - Proton pump inhibitors (omeprazole, esomeprazole): may reduce activation of clopidogrel. - Non‑steroidal anti‑inflammatory drugs (ibuprofen, naproxen): increase bleeding risk. - Anticoagulants (warfarin, direct oral anticoagulants): additive anticoagulant effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may modestly increase bleeding. - CYP2C19 inhibitors (fluconazole, fluoxetine): can affect clopidogrel metabolism. - Statins (simvastatin, atorvastatin): potential for increased plasma levels.